Following on from the identification of TM6SF2 as a modifier of NAFLD, a recent study has established that the rs58542926 variant was independently associated with HCC in patients with ALD (OR = 1.79 [CI 95%:1.25–2.56]) [69]. This evidence concerns the gene TM6SF2 and hepatocellular carcinoma.